Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women

@article{Hemelaar2006LessEO,
  title={Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women},
  author={Majoie Hemelaar and Jan Rosing and Peter Kenemans and M C Thomassen and Didi D.M. Braat and Marius Jan van der Mooren},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology},
  year={2006},
  volume={26},
  pages={1660-1666}
}
Objective—To compare the effects of intranasal and oral administration of 17&bgr;-estradiol (E2) and norethisterone(acetate) [NET(A)] in healthy postmenopausal women on activated protein C (APC) resistance and other hemostatic parameters associated with venous thrombosis. Methods and Results—In this 2-center, randomized, double-blind, 1-year trial, 90 postmenopausal women (56.6±4.7 years of age) received daily either an intranasal spray with 175 &mgr;g/275 &mgr;g E2/NET (n=47) or 1 mg/0.5 mg… 

Figures and Tables from this paper

Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial

During intranasal E2/NET therapy, changes in the coagulatory and fibrinolytic markers were to some extent less than those observed during oral therapy.

Plasma fibrin clot properties in postmenopausal women: effects of hormone therapy

Estrogen plus progestogen therapy has a minor effect on plasma fibrin properties, but leads to the formation of thicker and more branched fibr in fibers, particularly during oral administration.

Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen

Transdermal estrogens combined with norpregnanes may induce APC resistance and activate blood coagulation and provide a biological support to epidemiological data regarding the potential thrombogenic effects of norPregnanes.

Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy

One year of nasal PHT gave a smaller, although not statistically significant, increase in mammographic density than oral PHT, and issues are the relation between the route of administration of PHT and breast complaints and breast cancer risk.

Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens

Increased thrombin generation can be detected in women using hormone therapy, but this hypercoagulable phenotype depends both on the route of estrogen administration and the type of progestogens.

Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study

The nanostructured formulation is safe and effective in re-establishing optimal serum levels of estradiol and follicle-stimulating hormone and relieving the symptoms of menopause and may alleviate climacteric symptoms in postmenopausal women.

Pharmacology of Hormone Replacement Therapy in Menopause

Preceded by endocrine and menstrual cycle changes described as “menopausal transition”, natural menopause occurs at an average age of approximately 51 years, although a high inter-individual variability is supported by results from epidemiological studies.

Menopause, menopausal therapies and asymmetric dimethylarginine, an emerging cardiovascular risk factor

Oestrogenen en asymmetrische dimethylarginine Hart- en vaatziekten (HVZ) vormen de belangrijkste doodsoorzaak in de Westerse wereld. Premenopauzale vrouwen hebben een lager risico op HVZ dan mannen

References

SHOWING 1-10 OF 38 REFERENCES

Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women

The increase in resistance to APC was not explained by changes in protein S, protein C, or prothrombin and may contribute to the increased incidence of venous thrombosis in users of hormone replacement therapy.

Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial

The data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation, and emphasize the importance of the route of estrogen administration.

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.

Low-dose oral estradiol therapy was associated with an increase in fibrinolysis and small decreases in procoagulant variables and transdermal therapy had minor effects.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis.

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial

It is concluded that HRT diminishes the efficacy by which APC downregulates in‐vitro thrombin formation in a similar fashion to that observed with low‐dose oral contraceptives, but the increase in nAPCsr alone is not sufficient to explain the increased risk of VTE associated with use of HRT.

Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.

Intranasal administration of 300 microg/d estradiol was at least as effective as oral administration of 2 mg/dEstradiol in alleviating postmenopausal symptoms, with less frequent mastalgia and uterine bleeding and without the metabolic consequences of the first-pass effect.

Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.

  • Medicine, Biology
    Thrombosis and haemostasis
  • 1996
Both regimens produce a clinically relevant decrease of fibrinogen levels; the continuous regimen affects also the levels of FVII and inhibitors suggesting that the haemostatic balance is shifted to a more physiological state.

The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.

It is concluded that HRT was associated with early activation of coagulation, which corroborates the finding of an early risk of recurrent VTE and may be explained by reduction in circulating anticoagulants.

Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.

It is concluded that use of HRT containing estradiol was associated with a threefold increased risk of VTE, but this increased risk was restricted to the first year of use.